The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

"The lack of a significant link between AmygA and LN metastasis in premenopausal women suggests that menopausal status may ...

Part of that spike is due to rising rates of cancers that affect primarily women, including breast cancer and endometrial ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

Cancer incidence continues to rise for many common cancers—especially for women. The incidence rate for women younger than 50 ...

The risk and incidence of cancer among people under 50 is also on the rise, according to American Cancer Society.

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

This has been linked to lifestyle changes, metabolic diseases, and obesity, with cases increasingly being reported in women ...

Use of long-acting, reversible contraceptives is associated with an increased risk of certain cancers, a study suggests.